BI-1607

BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab.

12352203

Fc Receptor (FcR)

Immunology/Inflammation

Cancer-programmed cell death

Cancer

[1]Cortés J, et al. Abstract PO1-18-06: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors–CONTRAST[J]. Cancer Research, 2024, 84 (9_Supplement) : PO1-18-06-PO1-18-06. |[2]Cortés J, et al. Abstract PO1-18-06: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors–CONTRAST[J]. Cancer Research, 2024, 84 (9_Supplement) : PO1-18-06-PO1-18-06.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991582/

Inhibitory Antibodies

No Development Reported